These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The case for medical treatment in chronic stable coronary artery disease. Nash DT Arch Intern Med; 2005 Dec 12-26; 165(22):2587-9, discussion 2593-4. PubMed ID: 16344414 [No Abstract] [Full Text] [Related]
3. Can pravastatin lower coronary event rate if HDL and LDL cholesterol are at low levels? Maron DJ Nat Clin Pract Cardiovasc Med; 2004 Nov; 1(1):18-9. PubMed ID: 16265253 [No Abstract] [Full Text] [Related]
4. [Can higher level of HDL cholesterol augment cardiovascular disease prevention? The combination statins-nicotinic acid increases the level of HDL and reduces the level of LDL cholesterol]. Carlson LA Lakartidningen; 2006 Oct 25-31; 103(43):3283-5. PubMed ID: 17117660 [No Abstract] [Full Text] [Related]
5. Focus on HDL as a therapeutic target for CAD risk reduction. Davidson MH Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937 [No Abstract] [Full Text] [Related]
6. Statins. Cholesterol treatment and beyond. Mayo Clin Health Lett; 2004 Nov; 22(11):1-3. PubMed ID: 15619748 [No Abstract] [Full Text] [Related]
7. Goals for cholesterol lowering. Stankler L Circulation; 1999 May; 99(18):2477. PubMed ID: 10318741 [No Abstract] [Full Text] [Related]
12. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A; Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888 [TBL] [Abstract][Full Text] [Related]
13. Changing face of dyslipidemia therapy. Banerjee AK Indian Heart J; 2008; 60(3):192-4. PubMed ID: 19240305 [No Abstract] [Full Text] [Related]
14. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. Clearfield M; Downs JR; Lee M; Langendorfer A; McConathy W; Gotto AM Am J Cardiol; 2005 Dec; 96(12):1674-80. PubMed ID: 16360356 [TBL] [Abstract][Full Text] [Related]
16. Aggressive medical therapy for the prevention and treatment of coronary artery disease. Malloy MJ; Kane JP Dis Mon; 1998 Jan; 44(1):1-40. PubMed ID: 9457050 [No Abstract] [Full Text] [Related]
17. Rationale for aggressive lipid lowering: evidence from clinical trials. Farmer JA Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477 [No Abstract] [Full Text] [Related]
18. [Lower LDL and/or raise HDL. In what direction is lipidology moving?]. Parhofer KG MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222 [No Abstract] [Full Text] [Related]
19. Cholesteryl ester transfer protein TaqIB polymorphism in the cholesterol and recurrent events study. Marian AJ Curr Atheroscler Rep; 2005 May; 7(3):178-9. PubMed ID: 15811250 [No Abstract] [Full Text] [Related]
20. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c. Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL; Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]